While Bicara Therapeutics Inc has overperformed by 1.83%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCAX fell by -45.69%, with highs and lows ranging from $28.09 to $7.80, whereas the simple moving average fell by -40.86% in the last 200 days.
On May 23, 2025, Wells Fargo Upgraded Bicara Therapeutics Inc (NASDAQ: BCAX) to Equal Weight. A report published by Wells Fargo on April 17, 2025, Initiated its previous ‘Underweight’ rating for BCAX. Wedbush also rated BCAX shares as ‘Outperform’, setting a target price of $31 on the company’s shares in an initiating report dated February 06, 2025. H.C. Wainwright Initiated an Buy rating on December 06, 2024, and assigned a price target of $42. Rodman & Renshaw initiated its ‘Buy’ rating for BCAX, as published in its report on November 05, 2024. Stifel also rated the stock as ‘Buy’.
Analysis of Bicara Therapeutics Inc (BCAX)
One of the most important indicators of Bicara Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 24.62, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and BCAX is recording 888.43K average volume. On a monthly basis, the volatility of the stock is set at 9.09%, whereas on a weekly basis, it is put at 8.75%, with a loss of -0.53% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.60, showing growth from the present price of $9.46, which can serve as yet another indication of whether BCAX is worth investing in or should be passed over.
How Do You Analyze Bicara Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 39.92%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 62.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BCAX shares are owned by institutional investors to the tune of 62.30% at present.
